Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Zacks News
Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan
by Zacks Equity Research
The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.
Myriad Genetics' Test Added in Disease Activity Measure List
by Zacks Equity Research
Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.
Myriad Genetics Presents New Test Data in Autoimmune Segment
by Zacks Equity Research
Myriad Genetics (MYGN) presents key findings related to Vectra test from its autoimmune segment.
Company News For Nov 6, 2019
by Zacks Equity Research
Companies In The News Are: CPE, EVER, MYGN, AAN
Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.
Myriad Genetics (MYGN) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of -75.76% and -8.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod
by Zacks Equity Research
Myriad Genetics (MYGN) moves a step toward advanced treatment by identifying women with ovarian cancer, who are currently receiving chemotherapy.
Myriad (MYGN) Up 5.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.
Myriad Genetics (MYGN) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of -12.77% and -2.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
What's in the Offing for Cisco Systems' (CSCO) Q4 Earnings?
by Zacks Equity Research
Cisco (CSCO) is benefiting from its expanding footprint in the rapidly growing security market. Also, partnerships and synergies from acquisitions will boost the company's revenue base.
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
by Zacks Equity Research
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics Divests NAMIC Portfolio to Medline Industries
by Zacks Equity Research
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
Myriad Genetics Announces Study Results Of myRisk Cancer Test
by Zacks Equity Research
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
Myriad Genetics' (MYGN) POLO Study Shows Positive Results
by Zacks Equity Research
Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.
Why Should You Hold on to Myriad Genetics (MYGN) Stock?
by Zacks Equity Research
Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).
Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
Myriad Genetics (MYGN) Beats Q3 Earnings Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck
by Zacks Equity Research
The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.
Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake
by Zacks Equity Research
The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.